+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication



Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication



European Journal of Clinical Pharmacology 30(5): 527-533



17 patients with severe digoxin intoxication were successfully treated with 320 to 480 mg Fab fragments of digoxin-specific IgG from sheep. The infusion period ranged between 0.5 and 7 h. Serum and urine concentrations of digoxin bound to Fab fragments, and in 11 cases unbound Fab fragments in serum, were determined during and after the infusion. The renal clearance of bound digoxin and therefore of the antibody was 13.6 ml/min. The median extrarenal clearance of the Fab fragments was 10.9 ml/min. The half-life of the serum concentrations starting at 12 h was 14.3 h, and the value was increased to 25.4 h when regression began at 24 h; the corresponding apparent distribution volumes were 25.9 and 541. These figures exceed the volume of the extracellular space and suggest intracellular penetration of the Fab fragments. The dosage of the antibody should be sufficiently high to bind digoxin in the most severe cases of poisoning. The maximum serum concentrations of bound antibody were 30 mg/l after 3 h and 20 mg/l after 5 h. A loading dose of 160 mg followed by an infusion of 0.5 mg/min was sufficient to absorb digoxin re-diffusing into the serum during the first 8 h. In some cases free digoxin reappeared in the serum 8-12 h after beginning the treatment. This might be prevented by infusing a further ampoule at a rate of 0.1 mg/min or less.

(PDF emailed within 0-6 h: $19.90)

Accession: 040540288

Download citation: RISBibTeXText

PMID: 3758140

DOI: 10.1007/bf00542410


Related references

Severe digoxin intoxication in a child treated by infusion of digoxin-specific Fab-antibody-fragments. European Journal of Pediatrics 142(2): 138-140, 1984

Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. New England Journal of Medicine 294(15): 797-800, 1976

Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity. British Journal of Clinical Pharmacology 28(3): 352-356, 1989

Use of digoxin-specific antibody fragments in treatment of digoxin intoxication in hemodialysis patients. Journal of the American Society of Nephrology 5(3): 469, 1994

Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies. Therapeutic Drug Monitoring 14(2): 147-154, 1992

Immediate control of life-threatening digoxin intoxication in a child by use of digoxin-specific antibody fragments (Fab). Paediatric Anaesthesia 13(6): 541-549, 2003

Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis. American Journal of Nephrology 10(6): 518-521, 1990

Digoxin-specific antibody fragments for the treatment of digoxin intoxication. Clinical Pharmacy 5(10): 826-827, 1986

Digoxin intoxication in a patient with end-stage renal disease: efficacy of digoxin-specific Fab antibody fragments and peritoneal dialysis. Therapeutic Drug Monitoring 19(5): 510-515, 1997

The pharmaco kinetics of digoxin acetyl digoxin and methyl digoxin in healthy and sick persons. Verhandlungen der Deutschen Gesellschaft fuer Innere Medizin 79: 1037-1039, 1973

Digoxin and a clinical evaluation of three digoxin methods, microgenic CEDIA Digoxin Plus, Dade Stratus digoxin and Technicon Immuno 1. Clinical Chemistry 40(6): 1082, 1994

The plasma kinetics of digoxin-specific Fab fragments and digoxin in the rabbit. Journal of Pharmacy and Pharmacology 43(11): 807-810, 1991

Enhanced Clearance of Specifically Bound Digoxin from Human Myocardial and Skeletal Muscle Samples by Specific Digoxin Antibody Fragments. Journal of Cardiovascular Pharmacology 17(4): 670-677, 1991

Treatment of severe digoxin toxicity with digoxin-specific antibody fragments. Anaesthesia and Intensive Care 15(2): 234-236, 1987

Digoxin toxicity in a premature infant: treatment with Fab fragments of digoxin-specific antibodies. Pediatric Cardiology 6(2): 91-93, 1985